HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Shares of HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) have been given an average rating of “Moderate Buy” by the six brokerages that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $14.87.

HCM has been the subject of several analyst reports. Bank of America dropped their price target on shares of HUTCHMED from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Tuesday, July 7th. HSBC upgraded shares of HUTCHMED from a “hold” rating to a “buy” rating in a report on Tuesday, September 8th. The Goldman Sachs Group reduced their price objective on shares of HUTCHMED from $16.00 to $14.00 and set a “neutral” rating on the stock in a research note on Thursday, July 23rd. Wall Street Zen upgraded HUTCHMED from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Finally, Weiss Ratings lowered HUTCHMED from a “hold (c-)” rating to a “sell (d)” rating in a research report on Friday, July 31st.

HUTCHMED Trading Down 3.0%

HUTCHMED stock opened at $13.68 on Tuesday. The business has a 50 day moving average of $13.22 and a 200-day moving average of $12.65. HUTCHMED has a 1 year low of $9.77 and a 1 year high of $16.33. The company has a quick ratio of 5.50, a current ratio of 5.64 and a debt-to-equity ratio of 0.06.

HUTCHMED (NASDAQ:HCM) last posted its earnings results on Thursday, July 30th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.14 by ($0.09). The company had revenue of $139.14 million for the quarter, compared to analyst estimates of $304.16 million. On average, analysts anticipate that HUTCHMED will post 0.23 earnings per share for the current fiscal year.

Institutional Investors Weigh In On HUTCHMED

Several institutional investors and hedge funds have recently made changes to their positions in HCM. XY Capital Ltd raised its position in shares of HUTCHMED by 115.2% during the second quarter. XY Capital Ltd now owns 104,130 shares of the company’s stock worth $1,120,000 after acquiring an additional 55,736 shares during the last quarter. Janney Montgomery Scott LLC bought a new stake in HUTCHMED in the first quarter valued at approximately $365,000. Finally, Amundi boosted its holdings in HUTCHMED by 4.0% in the first quarter. Amundi now owns 232,246 shares of the company’s stock valued at $3,474,000 after acquiring an additional 8,916 shares during the last quarter. Institutional investors and hedge funds own 8.82% of the company’s stock.

About HUTCHMED

HUTCHMED (NASDAQ:HCM) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and immunological diseases. Founded in 2000, the company has built an integrated research and development platform spanning drug discovery, clinical development, regulatory activities and commercialization.

HUTCHMED’s portfolio includes targeted therapies and other treatments for solid tumors and hematologic malignancies. Its medicines include fruquintinib, marketed in China as Elunate and in the United States as Fruzaqla, and savolitinib, marketed in China as Orpathys through a collaboration with AstraZeneca.